Recurrency rate influencing effect on intravesical Lycurim treatment in transurethrally resected bladder tumours.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004896:Erythritol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*
D000970:Antineoplastic Agents; D004896:Erythritol; C000288:ritrosulfan